Technical Analysis for SAR - Sareum Holdings Plc

Grade Last Price % Change Price Change
C 6.1 6.09% 0.35
SAR closed down 2.54 percent on Monday, November 29, 2021, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It ran into resistance at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical SAR trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 6.09%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 6.09%
20 DMA Support Bullish 6.09%
Calm After Storm Range Contraction 6.09%
NR7 Range Contraction 6.09%
Stochastic Reached Overbought Strength 6.09%
Inside Day Range Contraction 6.09%
Wide Bands Range Expansion 6.09%
Overbought Stochastic Strength 6.09%
50 DMA Resistance Bearish 3.39%
Older End-of-Day Signals for SAR ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 10% about 6 hours ago
Rose Above Previous Day's High about 7 hours ago
50 DMA Resistance about 7 hours ago
Up 5% about 8 hours ago
Rose Above 50 DMA about 8 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Sareum Holdings Plc Description

Sareum Holdings plc is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's drug programs include Checkpoint Kinase 1 (CHK1), Aurora+FLT3 Kinase and Tyrosine Kinase 2- autoimmune diseases (TYK2), Aurora+FLT3 kinase and TYK2 kinase-cancer. Its Chk1 program is the advanced program and shows potency in disease models of lung and colon cancers in combination with chemotherapy; acute myeloid leukemia (AML) and B-cell lymphoma, and head and neck cancers in combination with radiotherapy. TYK2 kinase program focuses on developing a series of TYK2 inhibitors that can be dosed orally against various autoimmune and inflammatory disorders, including psoriasis and rheumatoid arthritis. Its Aurora+FLT3 Kinase program focuses on AML and other blood cancers. Its TYK2 kinase prevents T-cell acute lymphoblastic leukemia (T-ALL) cells from proliferating by causing programmed cell death.


Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Chemistry Disease Cancer Radio Branches Of Biology Diseases Drugs Therapy Biology Blood Rtt Autoimmune Diseases Disorders Skills Cancers Enzymes Medicinal Chemistry Radiotherapy Arthritis Chemotherapy Kinase Acute Myeloid Leukemia Inflammatory Disorders Leukemia Psoriasis Rheumatoid Arthritis Tyrosine Kinase

Is SAR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 10.0
52 Week Low 1.2
Average Volume 15,976,919
200-Day Moving Average 4.96
50-Day Moving Average 6.09
20-Day Moving Average 5.44
10-Day Moving Average 5.05
Average True Range 0.70
ADX 25.04
+DI 20.14
-DI 24.38
Chandelier Exit (Long, 3 ATRs) 4.79
Chandelier Exit (Short, 3 ATRs) 5.24
Upper Bollinger Bands 6.65
Lower Bollinger Band 4.22
Percent B (%b) 0.63
BandWidth 44.83
MACD Line -0.25
MACD Signal Line -0.36
MACD Histogram 0.1092
Fundamentals Value
Market Cap 187.89 Million
Num Shares 3.27 Billion
EPS -0.10
Price-to-Earnings (P/E) Ratio -57.50
Price-to-Sales 929.82
Price-to-Book 25.82
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.80
Resistance 3 (R3) 6.80 6.45 6.62
Resistance 2 (R2) 6.45 6.18 6.45 6.56
Resistance 1 (R1) 6.10 6.02 5.93 6.10 6.51
Pivot Point 5.75 5.75 5.66 5.75 5.75
Support 1 (S1) 5.40 5.48 5.23 5.40 4.99
Support 2 (S2) 5.05 5.32 5.05 4.94
Support 3 (S3) 4.70 5.05 4.88
Support 4 (S4) 4.70